secwatch.observer — SEC 8-K summary
======================================

Issuer:     PFIZER INC (PFE)
CIK:        0000078003
Form:       8-K
Filed at:   2024-10-29T23:59:59+00:00
Accession:  0000078003-24-000188
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pfizer Q3 revenue $17.7B (+32% YoY); raises FY 2024 guidance on revenue and EPS
-------------------------------------------------------------------------------

- Q3 2024 revenues of $17.7B, operational growth +32% YoY; ex-Paxlovid/Comirnaty revenue up 14% operationally.
- Reported diluted EPS $0.78 vs. ($0.42) in Q3 2023; adjusted diluted EPS $1.06 vs. ($0.17).
- Raised FY 2024 revenue guidance to $61-64B (from $59.5-62.5B) and adjusted EPS to $2.75-2.95 (from $2.45-2.65).
- Paxlovid revenue $2.7B (+$2.5B YoY); Comirnaty revenue $1.4B (+9% operational).
- Cost reduction program on track for at least $5.5B net savings; $4B expected by end of 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/78003/000007800324000188/0000078003-24-000188-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/78003/000007800324000188/pfe-20241029.htm
  HTML page:      https://secwatch.observer/filing/0000078003-24-000188

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer